🚀 VC round data is live in beta, check it out!
XBiotech Valuation Multiples
Discover revenue and EBITDA valuation multiples for XBiotech and similar public comparables like Q32 Bio, Paradigm Biopharma, PMV Pharma, MediciNova and more.
XBiotech Overview
About XBiotech
XBiotech Inc is a United States-based clinical-stage biopharmaceutical company. The company is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-inflammatory therapeutic antibodies as a treatment for cancer. Geographically, all of its operations are in the United States.
Founded
2005
HQ
Employees
92
Website
Sectors
Financials (FY)
Market Cap
$71M
XBiotech Financials
XBiotech reported last fiscal year revenue of — and negative EBITDA of ($44M).
In the same fiscal year, XBiotech generated ($44M) in EBITDA losses and had net loss of ($46M).
Revenue (LTM)
XBiotech P&L
In the most recent fiscal year, XBiotech reported revenue of — and EBITDA of ($44M).
XBiotech expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | — | XXX | ($44M) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($46M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
XBiotech Stock Performance
XBiotech has current market cap of $71M.
Market Cap Evolution
XBiotech's stock price is $2.34.
| Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|
| $71M | 0.2% | XXX | XXX | XXX | $-1.49 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialXBiotech Valuation Multiples
XBiotech trades at 2.1x EV/EBITDA.
EV / Revenue (LTM)
XBiotech Financial Valuation Multiples
As of April 11, 2026, XBiotech has market cap of $71M.
Equity research analysts estimate XBiotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
XBiotech has a P/E ratio of (1.6x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $71M | XXX | $71M | XXX | XXX | XXX |
| EV (current) | ($91M) | XXX | ($91M) | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 2.1x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 1.6x | XXX | XXX | XXX |
| P/E | — | XXX | (1.6x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | 2.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified XBiotech Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
XBiotech Margins & Growth Rates
XBiotech's revenue in the last fiscal year grew by —.
XBiotech's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.6M for the same period.
XBiotech Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | — | XXX | 21% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.6M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
XBiotech Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Q32 Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| Paradigm Biopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| PMV Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| MediciNova | XXX | XXX | XXX | XXX | XXX | XXX |
| IBT | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
XBiotech M&A Activity
XBiotech acquired XXX companies to date.
Last acquisition by XBiotech was on XXXXXXXX, XXXXX. XBiotech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by XBiotech
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialXBiotech Investment Activity
XBiotech invested in XXX companies to date.
XBiotech made its latest investment on XXXXXXXX, XXXXX. XBiotech invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by XBiotech
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout XBiotech
| When was XBiotech founded? | XBiotech was founded in 2005. |
| Where is XBiotech headquartered? | XBiotech is headquartered in United States. |
| How many employees does XBiotech have? | As of today, XBiotech has over 92 employees. |
| Who is the CEO of XBiotech? | XBiotech's CEO is Sushma Shivaswamy. |
| Is XBiotech publicly listed? | Yes, XBiotech is a public company listed on Nasdaq. |
| What is the stock symbol of XBiotech? | XBiotech trades under XBIT ticker. |
| When did XBiotech go public? | XBiotech went public in 2015. |
| Who are competitors of XBiotech? | XBiotech main competitors are Q32 Bio, Paradigm Biopharma, PMV Pharma, MediciNova. |
| What is the current market cap of XBiotech? | XBiotech's current market cap is $71M. |
| Is XBiotech profitable? | No, XBiotech is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.